Clinical Report: Staphylococcus aureus Serine Protease-Like Protein B Induces Immune Responses

Overview

This study demonstrates that Staphylococcus aureus serine protease-like protein B (SplB) significantly elevates IgE levels and induces T cell activation in patients with atopic dermatitis (AD). The findings suggest that SplB contributes to the inflammatory phenotype observed in AD.

Background

Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition characterized by type-2 immune responses. The skin microbiome, particularly Staphylococcus aureus, plays a crucial role in exacerbating AD through its pathogenic factors. Understanding the immune responses to S. aureus components, such as SplB, is essential for developing targeted therapies.

Data Highlights

Significantly elevated IgE levels specific for Spl proteins were found in AD patients compared to healthy controls. In vitro studies showed that recombinant SplB activates T cells and induces cytokine secretion.

Key Findings

• Elevated IgE antibodies specific for Spl proteins were observed in AD patients.
• Recombinant SplB induced T cell activation and cytokine secretion in both AD patients and healthy controls.
• SplB-specific T helper cells produced IFN-γ and IL-13 ex vivo.
• Clonal propagation of SplB-specific T cells was confirmed through TCR sequencing.
• SplB-specific TCR sequences were re-identified in lesional skin biopsies from AD patients.

Clinical Implications

The findings highlight the role of SplB in the immune response of AD, suggesting that targeting this pathway may provide new therapeutic strategies. Clinicians should consider the implications of S. aureus colonization in managing AD.

Conclusion

The study underscores the importance of S. aureus serine proteases in the immune dysregulation seen in atopic dermatitis, indicating potential avenues for therapeutic intervention.

Related Resources & Content

1. The Journal of Infectious Diseases, 2023 -- Neutrophil Elastase Limits Spread of Staphylococcus aureus during Skin Infection
2. Frontiers in Medicine, 2026 -- Association between Staphylococcus aureus colonization and clinical improvement in pediatric atopic dermatitis treated with dupilumab: a pilot study
3. Frontiers in Immunology, 2026 -- Synthetic short peptide mimicking IsdB and IsdH conserved motifs selectively bind and enable detection of Staphylococcus aureus infection
4. Atopic dermatitis clinical guideline, 2025 -- AAD Clinical Guidelines
5. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials - ScienceDirect
6. Frontiers in Immunology — Staphylococcus epidermidis prevents UV-induced skin aging by suppressing TLR3-mediated senescence
7. Atopic dermatitis clinical guideline
8. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials - ScienceDirect
9. Monoclonal antibody neutralizes Staphylococcus aureus serine protease-like protein B (SplB)-induced pathology | Infection and Immunity